

# Matthew J Schipper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/827042/publications.pdf>

Version: 2024-02-01

69  
papers

1,930  
citations

293460

24  
h-index

312153

41  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3668  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac Magnetic Resonance Imaging and Blood Biomarkers for Evaluation of Radiation-Induced Cardiotoxicity in Patients With Breast Cancer: Results of a Phase 2 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 417-425.	0.4	10
2	Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After $^{90}\text{Y}$ Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity. <i>Journal of Nuclear Medicine</i> , 2022, 63, 882-889.	2.8	2
3	Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 942-950.	0.4	7
4	Effect of Education and Standardization of Cardiac Dose Constraints on Heart Dose in Patients With Lung Cancer Receiving Definitive Radiation Therapy Across a Statewide Consortium. <i>Practical Radiation Oncology</i> , 2022, 12, e376-e381.	1.1	2
5	Early phase clinical trials extension to guidelines for the content of statistical analysis plans. <i>BMJ</i> , The, 2022, 376, e068177.	3.0	12
6	Racial Differences in Treatments and Toxicity in Patients With Non-Small-Cell Lung Cancer Treated With Thoracic Radiation Therapy. <i>JCO Oncology Practice</i> , 2022, , OP2100224.	1.4	0
7	Utility based approach in individualized optimal dose selection using machine learning methods. <i>Statistics in Medicine</i> , 2022, 41, 2957-2977.	0.8	2
8	Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients. <i>BJU International</i> , 2022, , .	1.3	2
9	Improved prediction of radiation pneumonitis by combining biological and radiobiological parameters using a data-driven Bayesian network analysis. <i>Translational Oncology</i> , 2022, 21, 101428.	1.7	6
10	Design and analysis considerations for utilizing a mapping function in a small sample, sequential, multiple assignment, randomized trials with continuous outcomes. <i>Statistics in Medicine</i> , 2021, 40, 312-326.	0.8	2
11	TNFR1 and the TNF axis as a targetable mediator of liver injury from stereotactic body radiation therapy. <i>Translational Oncology</i> , 2021, 14, 100950.	1.7	14
12	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
13	A Bayesian dose-finding design for outcomes evaluated with uncertainty. <i>Clinical Trials</i> , 2021, 18, 279-285.	0.7	0
14	Evaluation of predictive model performance of an existing model in the presence of missing data. <i>Statistics in Medicine</i> , 2021, 40, 3477-3498.	0.8	2
15	Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1176-1185.	0.4	21
16	In Regard to Lo et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1252.	0.4	1
17	A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 792-803.	0.4	23
18	Feasibility of function-guided lung treatment planning with parametric response mapping. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 80-89.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Prediction of Tumor Control in <sup>90</sup> Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 104-111.	2.8	36
20	A utility approach to individualized optimal dose selection using biomarkers. <i>Biometrical Journal</i> , 2020, 62, 386-397.	0.6	3
21	Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium. <i>Practical Radiation Oncology</i> , 2020, 10, e27-e36.	1.1	12
22	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	0.8	26
23	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58
24	Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics. <i>Radiotherapy and Oncology</i> , 2020, 148, 30-37.	0.3	15
25	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
26	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 313-319.	1.4	11
27	Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1635-1643.	1.2	24
28	Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16– High Risk Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1118.	1.3	17
29	Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 169-179.	0.4	46
30	Dosimetric impact of interfractional organs at risk variation during high-dose rate interstitial brachytherapy for gynecologic malignancies. <i>Medical Dosimetry</i> , 2019, 44, 239-244.	0.4	1
31	Changes in prostate orientation due to removal of a Foley catheter. <i>Medical Physics</i> , 2018, 45, 1369-1378.	1.6	13
32	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	0.9	29
33	Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 950-958.	0.4	59
34	Prediction of Radiation Esophagitis in Non–Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. <i>Translational Oncology</i> , 2018, 11, 102-108.	1.7	10
35	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.4	7
36	Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 107-114.	0.4	28

#	ARTICLE	IF	CITATIONS
37	Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 131-137.	0.4	18
38	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. <i>Practical Radiation Oncology</i> , 2018, 8, 40-47.	1.1	27
39	Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. <i>Radiotherapy and Oncology</i> , 2018, 126, 68-74.	0.3	74
40	Knowledge-based treatment planning and its potential role in the transition between treatment planning systems. <i>Medical Dosimetry</i> , 2018, 43, 251-257.	0.4	8
41	Impact of 90Y PET gradient-based tumor segmentation on voxel-level dosimetry in liver radioembolization. <i>EJNMMI Physics</i> , 2018, 5, 31.	1.3	4
42	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	2.6	6
43	Machine learning and modeling: Data, validation, communication challenges. <i>Medical Physics</i> , 2018, 45, e834-e840.	1.6	67
44	A simulation study to assess the potential impact of developing normal tissue complication probability models with accumulated dose. <i>Advances in Radiation Oncology</i> , 2018, 3, 662-672.	0.6	12
45	Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 757-764.	0.4	16
46	An analysis of knowledge-based planning for stereotactic body radiation therapy of the spine. <i>Practical Radiation Oncology</i> , 2017, 7, e355-e360.	1.1	38
47	Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. <i>European Urology</i> , 2017, 72, 617-624.	0.9	50
48	Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1358.	3.4	177
49	Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 539-546.	0.5	12
50	Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 309-319.	0.7	2
51	Big Data in Designing Clinical Trials: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 2017, 7, 187.	1.3	36
52	Predictors of severe long-term toxicity after re-irradiation for head and neck cancer. <i>Oral Oncology</i> , 2016, 60, 32-40.	0.8	30
53	Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. <i>Head and Neck</i> , 2016, 38, E1086-96.	0.9	41
54	Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 354-361.	0.4	63

#	ARTICLE	IF	CITATIONS
55	Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure. <i>Radiotherapy and Oncology</i> , 2016, 120, 81-86.	0.3	50
56	Impact of xerostomia on dysphagia after chemotherapyâ€“intensityâ€“modulated radiotherapy for oropharyngeal cancer: Prospective longitudinal study. <i>Head and Neck</i> , 2016, 38, E1605-12.	0.9	36
57	Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 305-311.	0.4	18
58	Enhancing safety and quality through preplanning peer review for patients undergoing stereotactic body radiation therapy. <i>Practical Radiation Oncology</i> , 2016, 6, e39-e46.	1.1	28
59	Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. <i>Oral Oncology</i> , 2016, 54, 68-74.	0.8	15
60	A Statistical Evaluation of Dose Expansion Cohorts in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	20
61	Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 75-81.	0.3	32
62	Single or multi-channel vaginal cuff high-dose-rate brachytherapy: Is replanning necessary prior to each fraction?. <i>Practical Radiation Oncology</i> , 2014, 4, 20-26.	1.1	15
63	Tumor-Absorbed Dose Predicts Progression-Free Survival Following <sup>131</sup> I-Tositumomab Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1047-1053.	2.8	51
64	KRAS Protein Stability Is Regulated through SMURF2: UBC5 Complex-Mediated $\beta$ -TrCP1 Degradation. <i>Neoplasia</i> , 2014, 16, 115-W5.	2.3	74
65	Comparing Long-Term Treatment-Associated Toxicities in Cancer Patients: Approaches, Caveats, and Recommendations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 232-234.	0.4	2
66	Evaluation of dual energy quantitative CT for determining the spatial distributions of red marrow and bone for dosimetry in internal emitter radiation therapy. <i>Medical Physics</i> , 2014, 41, 051901.	1.6	8
67	Personalized dose selection in radiation therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariates. <i>Statistics in Medicine</i> , 2014, 33, 5330-5339.	0.8	10
68	Prediction of Therapy Tumor-Absorbed Dose Estimates in I-131 Radioimmunotherapy Using Tracer Data Via a Mixed-Model Fit to Time Activity. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 403-411.	0.7	18
69	SBRT as an alternative to RFA for the treatment of primary and metastatic liver tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 158-158.	0.8	3